Public reporting burden for this collection of information is estimated to average 2 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0766). Do not return the completed form to this address.

	022 NCI SBIR Development Center Program with FDA CARE – Connecting Awardees with Regulatory Experts
* 1. Company Inf	ormation
Company Name	
Contact Person	
Title/Role	
Email	

\* 2. Please indicate the extent to which you agree with the following. Participation in the CARE Program helped our team...

	Strongly Agree	Agree	Disagree	Strongly Disagree
Learn and/or confirm the FDA Center (CBER, CDER, CDRH) or Office that will regulate our technology	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Begin developing the regulatory strategy for our technology	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Plan the next regulatory step(s) for our technology	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Clarify and/or confirm the appropriate regulatory path for our technology	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Gain a better understanding of the process to contact FDA for a meeting request	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Find information on FDA's website related to a particular regulatory topic	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Understand how to contact an FDA office that provides free resource assistance to industry (i.e., MATTB, SBIA, or DICE)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

## \* 3. Please indicate the extent to which you agree with the following. Following the CARE

Program, our team plans to...

	Strongly Agree	Agree	Disagree	Strongly Disagree
Contact an FDA office via phone or email that provides free resource assistance to industry (i.e., MATTB, SBIA, or DICE)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Watch an FDA webinar(s) on a particular regulatory topic	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Read an FDA guidance(s) on a particular regulatory topic	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Access an FDA website to learn more on a particular regulatory topic	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Submit a meeting request to FDA to discuss regulatory strategy (e.g., INTERACT meeting, pre-IND meeting, pre-submission meeting, etc.)	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

\* 4. Please indicate the extent to which you agree with the following. Our team...

	Strongly Agree	Agree	Disagree	Strongly Disagree
Found the CARE Program useful	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Found the NCI SBIR FDA resources website useful <u>https://sbir.cancer.gov/resources/fda-</u> <u>resources</u>	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Received information from the CARE Program that will affect our future SBIR/STTR specific aims	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$
Would recommend the CARE Program to other companies	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$

## 5. We welcome any additional feedback or comments you wish to provide.